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Huober: A highlight of this year’s ASCO was the presentation 
of the results of the EMILIA trial. In this randomized phase 3 
study T-DM1 was compared to lapatinib and capecitabine in 
patients with HER2-positive metastatic breast cancer after 
progression on trastuzumab based therapy. Interestingly 
T-DM1 a conjugate of a tubulin inhibiting agent and trastuzu-
mab was not only more effective in terms of increased PFS 
but also of better tolerability than lapatinib and capecitabine. 
Thomssen: For me, it is not possible to define one single high-
light. Actually, some topics made evident that, in general, 
 further improvements are rather complex; on the other hand 
some topics showed huge steps forward and opened new 
 options of treatment at least in the field of HER2 over-
expressing disease. Dual blockade of HER2 signaling, e.g. by 
combination of lapatinib and trastuzumab again proved 
 highest efficacy in the neoadjuvant situation (NSABP B-41) 
with pCR rates up to 70% as it has been shown previously 
in the NeoALTTO trial and also for the combination pertuzu-
mab and trastuzumab in the NeoSPHERE trial; these results 
may be transformed also into higher cure rates. In addition, 
the data of the EMILIA trial showed that a new cytotoxic 
compound that was linked to a specific transporter antibody, 
T-DM1, was significantly and substantially more effective in 
first-line therapy of HER2 overexpressing metastatic breast 
cancer than the standard combination capecitabine and 
lapatinib.
With more than 31,000 thousands participants, the Annual 
Meeting of the Society of Clinical Oncology 2012 June 1st–5th 
in Chicago was again both the largest meeting in oncology, 
but also overwhelming in the variety of scientific presenta-
tions as well as of educational and other sources of informa-
tion. 25% of the all presentations were dedicated to breast 
cancer, by the far the most elaborate coverage of any cancer 
entity.
With almost 1,400 participants, Germans were the largest 
country group after US attendees. We asked 6 German 
 experts about their bottom line of the ASCO 2012 meeting on 
5 burning questions.
Question 1: What Was Your Highlight of the Annual 
Meeting of the Society of Clinical Oncology 2012 in 
Chicago?
Möbus: The EMILIA study, which showed superiority of 
 trastuzumab-emtansine (T-DM1) in comparison with the 
 established standard of capecitabine and lapatinib in HER2-
positive patients who had failed on prior taxane and trastuzu-
mab treatment. This is a breakthrough in the therapeutic 
 options of breast cancer patients, who have failed first-line 
treatment. It is the first time that an antibody alone linked 
with a cytostatic drug (maytansine) shows superiority in 
 comparison with a combination therapy of a cytostatic drug 
and antibody treatment.
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Müller: In my opinion, no practice-changing trials were pre-
sented. Swain et al. (LBA 1000) showed results from the 
NSBP-38 trial that was not able to find a relevant difference 
between 3 different chemotherapy regimens, one including 
gemcitabine as additional drug. This indicates that further im-
provements in chemotherapy for unselected patient cohorts 
cannot be expected and that treatment has to be adapted for 
individual patients. With the approach of neoadjuvant ther-
apy, big improvements in the understanding of the tumor 
 biology were gained. In this context, the results of von Minck-
witz and coworkers are of relevance (abstract 1023). They 
 examined proliferation by immunohistochemistry for Ki-67 
in patients treated in the neoadjuvant Gepartrio trial. Post-
treatment Ki-67 adds independent and additional prognostic 
information on the outcome after surgery. Therefore, post-
treatment Ki-67 identifies groups of patients at high risk for 
relapse, for which additional post-surgical treatment options 
could be developed.
Huober: Adjuvant treatment after this year’s ASCO will 
 basically remain the same. Taxanes have been established 
in the adjuvant setting also in node-negative patients, and 
 targeted treatment with anti-HER2 agents is standard in the 
adjuvant and neoadjuvant setting in patients with HER2- 
positive tumors. We may have to rethink the strategy of dose 
dense therapy which was not superior to conventionally dosed 
anthracyclin taxane based adjuvant chemotherapy in the 
NSABP 38 study, enrolling almost 5,000 patients. The regi-
men with 4 × AC/EC followed by weekly paclitaxel (also a 
kind of dose dense treatment) remains one of our most valu-
able regimens in the adjuvant treatment of primary breast 
cancer. 
Thomssen: In metastatic disease, the new combinations and 
compounds for the treatment of HER-2 overexpressing breast 
cancer will enter our panel of therapeutic tools, very soon. 
Modern neoadjuvant trials do not work with single anti-
HER2 medication anymore; and the APHINITY trials looks 
at the combination pertuzumab-trastuzumab in the adjuvant 
therapy of HER2-positive breast cancer. 
Harbeck: As already stated by my colleagues, there will be no 
change in practice after ASCO 2012 in therapy for early 
breast cancer. The data of 2012 showed that we will not get 
any better by adding more therapy (and in particular chemo-
therapy) to unselected patient collectives. New studies need 
to show which new therapy concepts are important based on 
tumor biology. We will certainly move towards more neo-
adjuvant therapy in order to be able to tell our patients early 
about excellent response but also in order to introduce new 
therapy concepts in non-pCR (pathologic complete response) 
patients. Last but not least, the critical appraisal of adjuvant 
bisphosphonate therapy showed that most evidence across 
 trials is available for postmenopausal patients. 
On the other hand two topics were less encouraging. Prob-
ably due to unsatisfactory management of side effects, the 
new and promising drugs lapatinib and nab-paclitaxel failed 
to show enhanced benefit for our patients although first data 
indicated high efficacy. As a further topic and important 
 result, both, high level gene profiling and new targeted drugs 
demonstrated each interesting signals; however, the correla-
tions between gene alterations and predicted effects were still 
disappointing. Thus, a substantial amount of research still has 
to be done.
von Minckwitz: No doubt, the EMILIA data were most over-
whelming. Not surprisingly, I also found our own data on Ki67 
very interesting, which could serve as a meaningful predictive 
marker on future neo-adjuvant studies.
Harbeck: This year, I do certainly agree with the ASCO 
 organizers – the data of the EMILIA study as presented in the 
presidential plenary was certainly the breast cancer highlight 
of this year’s ASCO. This T-DM1 registration trial not only 
presents a new option for HER2-positive breast cancer, it 
also demonstrates the efficacy of a new therapeutic concept, 
an antibody drug conjugate. As speculated already about 
100 years ago by Paul Ehrlich, such ‘magic bullets’ may 
change cancer medicine by providing highly specific therapy 
without many systemic side effects. 
Janni: The data on HER2 targeted treatment, like the 
EMILIA data, was spectacular. We are closer to cure HER2-
positive disease than ever. However, many questions on 
 sequencing and combinations remain to be answered in order 
to provide both targeted and personalized treatment.
Question 2: What Changes in the Primary Treatment 
of Breast Cancer Were Triggered by ASCO 2012?
Möbus: Primary Treatment should not be changed! Some 
 colleagues may argue that we should stop giving chemo-
therapy to patients with a low number of positive nodes who 
have luminal A breast cancer subtype. However the declining 
breast cancer mortality rate observed over the last two de-
cades is, at least in part, due to the widespread use of adjuvant 
chemotherapy. In our intention to personalize breast cancer 
care, we must be careful not to dilute the impressive results of 
today’s standard of adjuvant treatment. Evidence supporting 
the theory of chemotherapy resistance in luminal A cancers is 
mainly based on retrospective subgroup analyses. I recom-
mend routine administration of adjuvant chemotherapy, until 
the results of prospective randomized trials, such as TAI-
LOR-X, MINDACT, and RxPONDER have been reported.
von Minckwitz: I agree, there should be no changes to the pri-
mary treatment of breast cancer based on the ASCO 2012 data.
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 remain in second line. HER2-positive disease will develop 
into the most favorable entity in terms of prognosis. However, 
it remains unclear whether triple positive disease needs a 
 different treatment strategy.
Thomssen: In terms of therapy, the neoadjuvant approach 
seems to be most adequate in HER2 overexpressing breast 
cancer. I assume that in the near future combined therapies 
consisting of two compounds that interact with the HER2 
 receptor in combination with an anthracycline-taxane chemo-
therapy sequence will be standard for this purpose. This refers 
to antibody-TKI-combinations (trastuzumab-lapatinib) as 
well as to antibody-antibody combinations (trastuzumab- 
pertuzumab). The chemotherapy loaded antibody T-DM1 will 
be introduced into first-line therapy of metastatic breast 
 cancer very soon; however, the logical next step in this situa-
tion might be the combination of pertuzumab and T-DM1. 
Another relevant option is the development of mTOR-inhibi-
tors (e.g. everolimus) that interact also in the HER2 signalling 
cascade and may be helpful in resistance to anti-HER2 
 directed therapy. Minimizing side effects of treatment will be 
another issue of therapy development.
In terms of prediction, additional markers, e.g. alterations 
in the PI3K-pathway, will be studied. Also neoadjuvant 
 therapy might be used as a dynamic predictive marker. In 
non-responders the use of T-DM1 is discussed and will be 
studied. As a further point, also ER-expression has a predic-
tive impact, indicating fewer responses to neoadjuvant 
 therapy in HER2 overexpressing tumors, thus suggesting 
 trials on alternative therapy combinations.
Harbeck: Together with the data for T-DM1 and pertuzumab 
already mentioned by my colleagues, we will see HER2-posi-
tive advanced breast cancer to move towards becoming a 
chronic disease. When these two drugs are registered, we will 
have – together with trastuzumab and lapatinib, four regis-
tered options. Moreover, a phase III registration trial for the 
irreversible panHER inhibitor afatinib is currently on the 
way. We now need to learn how to optimally use these drugs 
in combination or in sequence. It is very good that we will be 
able to use all of these new compounds in further trials, also 
in primary breast cancer, such as in the WSG-ADAPT trial, 
here in Germany. 
Question 4: Do You See Any Meaningful 
 Improvements in the Treatment of Triple-Negative 
Breast Cancer?
Möbus: I’m afraid that ‘no’ is the correct answer. Even after 
ASCO 2012, targeted treatment of triple-negative breast 
 cancer based on genotype, biologically distinct molecular sub-
types or other markers of heterogeneity is rather unlikely. 
Triple-negative breast cancer is a heterogeneous disease and 
Question 3: What, in Your Opinion, Will Be the  
Development in the Treatment of HER2-Positive  
Breast Cancer?
Möbus: Regarding primary systemic treatment – independent 
of adjuvant or neoadjuvant administration – we strongly move 
towards a cure for HER2 positive breast cancer patients. Dual 
blockade of the HER2 receptor will become the accepted 
standard of care. But we also must develop strategies to ‘dees-
calate’ the treatment, e.g. the duration of therapy in patients 
with pCR after neoadjuvant treatment. Regarding metastatic 
disease the clinical application of new targeted drugs like 
 pertuzumab and T-DM1 will further improve overall survival 
and optimize the patients’ quality of life.
Müller: With the presentation of the EMILA trial (abstract 
LBA 1) comparing T-DM1 with capecitabine and lapatinib in 
HER2-positive metastatic breast cancer, Blackell et al. 
showed results with a relevant improvement by the novel 
 approach of T-DM1 over the currently approved standard. 
Together with data on targeting of HER2 with trastuzumab 
combined either with the novel antibody pertuzumab or the 
tyrosine kinase inhibitor lapatinib, the perspective of further 
big improvements also in the adjuvant setting is open.
Huober: The number of available anti-HER2 agents in-
creases. The challenge for the future will be the optimal use 
of these agents in the metastatic setting and to select and 
 successfully transfer the most effective agents to the adjuvant 
setting. Several trials showed that dual blockade of the HER2 
receptor with two different anti-HER2 agents is a very 
 promising treatment strategy and this may give us the oppor-
tunity to delay chemotherapy in many patients with HER2-
positive metastatic breast cancer. This important topic will be 
investigated in an international first-line trial (SAKK 22/10). 
Patients will be randomized to receive pertuzumab and trastu-
zumab versus the same treatment in combination with chemo-
therapy. Endocrine treatment will be added if hormone 
 receptors are positive, which appreciates the different nature 
of the HER2- and estrogen receptor (ER)-positive disease. 
In case of progression all patients will be treated with T-DM1 
in second line. 
Another important challenge in the treatment of HER2 
positive disease will be reliable HER2 testing. We presented 
at ASCO data from the neoadjuvant GeparQuattro trial 
where in 27% of patients the locally determined HER2-posi-
tive result could not be confirmed by central testing. This was 
clinically relevant since the response rate to trastuzumab plus 
chemotherapy was significantly lower in these centrally 
HER2-negative tumors.
von Minckwitz: I agree, it is the increasing number of HER2 
targeted agents. Pertuzumab and T-DM1 will only stay tem-
porarily in the metastastic setting. Lapatinib will probably 
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therapeutics. PARP inhibitors are also further explored. Yet, 
we should not forget that at least in early breast cancer, about 
40% of triple-negative breast cancers respond extremely well 
to standard anthracycline-taxane-based chemotherapy. 
 Recently, adding bevacizumab has further improved pCR 
rates in triple-negative breast cancer. As mentioned by Jens 
Huober, the results of BEATRICE are eagerly awaited in 
order to address the role of VEGF inhibition in primary 
 triple-negative breast cancer. 
Question 5: What Do You Expect of ASCO 2013?
Möbus: Modern endocrine and chemotherapeutic treatment 
will remain the cornerstone of adjuvant therapy. ASCO 
should focus on translational and clinical research which deals 
with better defined targets. Only such an approach can avoid 
the problems of the last decade, where large clinical trials 
have failed because so-called ‘targeted therapy’ was based 
on limited preclinical data or inappropriate definition of 
the target.
Müller: I think one of the most important clinical challenges 
is the improvement of treatment for triple-negative patients. 
An additional challenge is the increasing number of brain 
 metastases, with currently little progress in the clinical 
management.
 
Huober: I expect more data about potential predictive factors 
especially for the increasing number of new drugs. 
Thomssen: Research focusing on HER2 overexpressing dis-
ease has shown huge successes. However, most breast cancers 
are HER2-negative, and for many of these cancers we do not 
have adequate therapies. In anti-angiogenic therapy, we still 
do not treat specifically enough, such that I wish that in the 
next 12 months a predictive marker may be found. In addi-
tion, facing the new technologies of genome and mutation 
profiling, I hope that more insights will lead to more targeted 
and more effective therapy approaches which was not con-
vincing at ASCO 2012. 
von Minckwitz: For now, I focus on the SABCS 2012, which 
will provide very interesting data: the Beatrice study, the 
HERA study, more survival data on the EMILIA and 
 Cleopatra studies and maybe more on bevacizumab and 
 endocrine treatment. This will be exciting.
Harbeck: I would love to see new study concepts and results 
that help us in daily clinical practice with tumor biology based 
treatment decisions. Moreover, it would be nice to see more 
trail data from our own German trials which will then be able 
to impact our guidelines (AGO, S3) as well. 
its diversity hinders detection of therapeutically competent 
markers. To further complicate matters, each metastasis may 
have a molecular signature that differs from other metastases 
or the primary cancer.
Müller: For triple-negative breast cancer, relatively few new 
results were shown, in my view none of them promising a 
 relevant improvement. Gucalp et al. (abstract 1006) showed a 
study that targeted the androgen receptor (AR) in women 
with AR+ ER–/progesterone receptor negative (PR–) meta-
static breast cancer. They found that 12% of ER–/PR– 
 patients are AR+. They stated (based on preliminary results 
from a small clinical study) that for these patients, AR inhibi-
tion with the AR antagonist bicalutamide is feasible, well 
 tolerated, and has activity based on pre-specified criteria. 
 Several presentations tried to improve the understanding of 
the heterogeneous biology of triple-negative breast cancer. 
As an example, Shapiro and coworkers (abstract 1007) used 
microRNA (miR) expression profiling to identify distinct 
 subclasses of triple-negative breast cancers. They stated that 
miR expression profiling identifies and discriminates five sub-
classes, which do not coincide with those identified as basal 
and non-basal by immunohistochemistry. However, none of 
the currently described classifiers has led to relevant improve-
ments in the treatment of patients.
Huober: There are still many open questions in triple-nega-
tive disease. We know that this subgroup is not as homogene-
ous as initially thought. The significance of platinum based 
treatment is still under discussion and new neoadjuvant data 
from the Spanish SOLTI Group showed good tolerability of 
olaparib with paclitaxel, however, similar pCR rates com-
pared to paclitaxel alone. The results of the Beatrice trial will 
show us in the future whether adjuvant bevacizumab will im-
prove outcome. 
Thomssen: Optimal treatment of triple-negative breast cancer 
is still not known. At ASCO 2012 many researchers focused 
on better characterization of triple-negative breast cancer. 
However, today we have to treat triple-negative breast cancer 
with the same drugs as non- triple-negative cancers.
von Minckwitz: For the moment, I don’t see any light at the 
horizon. Maybe in future, androgen receptor inhibitors might 
prove to be helpful.
Harbeck: I certainly agree with my colleagues that the 
 advances in triple-negative disease are slow. After getting our 
hopes up maybe too high with the exciting data on PARP 
 inhibitors, we have now learned that triple-negative breast 
cancer is quite heterogeneous. There are functional tests 
under development for impaired DNA repair mechanisms 
which would be clinically useful for indicating DNA damaging 
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Janni: In my opinion, the next step beyond targeted treatment 
of the tumor should be personalized treatment, with more 
predictive tools to guide length, combination, and sequence of 
treatment. Whether these tools will be molecular tests, circu-
lating tumor cells or other markers probably remains not only 
for ASCO 2013 but also 2023.
Participants
Prof. Dr. med. Nadia Harbeck
Brustzentrum der Universität München
Frauenkliniken Großhadern and Maistrasse-Innenstadt
Marchioninistr. 15, 81377 München, Germany 
Tel. +49 89 7095-7581, Fax -7582
Nadia.Harbeck@med.uni-muenchen.de
Prof. Dr. Jens Huober 
Frauenklinik, Bereich konservative Gynäkologische Onkologie 
Klinikum der Heinrich-Heine-Universität Düsseldorf 
Moorenstrase 5, 40225 Düsseldorf, Germany
Tel. +49 211 81–08087, Fax -18483
Jens.Huober@med.uni-duesseldorf.de
